NCT06671054 - A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG

AP1189, 40 mg

AP1189 tablets for oral use

DRUG

AP1189, 70 mg

AP1189 tablets for oral use

DRUG

AP1189, 100 mg

AP1189 tablets for oral use

DRUG

AP1189 matching placebo

AP1189 tablets for oral use

Trial Locations (11)

1431

RECRUITING

Diagnostic Consultative Center Aleksandrovska, Sofia

2068

RECRUITING

"IMSP Spitalul Clinic Municipal Sfanta Treime", Chisinau

2730

RECRUITING

Sanos Clinic Herlev, Herlev

3000

RECRUITING

Medical Center Tera Medico, Vratsa

16635

RECRUITING

Altoona Center for Clinical Research, Duncansville

33126

RECRUITING

Millennium Medical Research LLC, Miami

33189

RECRUITING

Nouvelle Clinical Research LLC, Cutler Bay

41-500

RECRUITING

M2Mmed, Chorzów

RECRUITING

Vita Longa Sp. z o. o., Katowice

60-218

RECRUITING

Medyczne Centrum Hetmańska, Poznan

58-100

RECRUITING

DC-MED Michal Kowalski S.K., Swidnica

All Listed Sponsors

collaborator

NBCD A/S

INDUSTRY

lead

SynAct Pharma Aps

INDUSTRY